Payment overview · 2025
General Payments
$47,219.36
179 reported records · 27 companies
Healthcare provider profile · identity verified
Thomas A. Kintanar, MD
Allopathic & Osteopathic Physicians|Family Medicine · FORT WAYNE, IN · NPI 1750326351
Verified facts
What the public records show
CMS Open Payments records show Thomas A. Kintanar, MD received $47,219.36 in general payments during 2025 across 179 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Trintellix, Ubrelvy, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Auvelity by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 677 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Lantus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17,173.23 | 36.4% | 15 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14,211.90 | 30.1% | 16 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $8,994.57 | 19.1% | 13 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4,516.19 | 9.6% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $380.31 | 0.8% | 24 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $261.86 | 0.6% | 27 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $226.88 | 0.5% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $215.66 | 0.5% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $201.67 | 0.4% | 9 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $157.47 | 0.3% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $142.38 | 0.3% | 8 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $131.01 | 0.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $98.46 | 0.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.14 | 0.2% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $78.39 | 0.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $62.44 | 0.1% | 3 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $44.62 | 0.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $33.96 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.64 | 0.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.41 | 0.1% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $26.57 | 0.1% | 1 | 2025 |
| Olympus America Inc. | Unresolved — no canonical attribution shown | $23.68 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.71 | 0.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.50 | 0.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.73 | 0.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.57 | 0.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.41 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $36,434.00 | 18 |
| Travel and Lodging | $6,616.85 | 14 |
| Food and Beverage | $4,097.29 | 141 |
| Education | $71.22 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17,173.23 | 15 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $14,404.56 | 21 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $8,994.57 | 13 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4,516.19 | 9 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $215.66 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $177.16 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $173.56 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $168.50 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $167.74 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $157.47 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $148.52 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $142.38 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $112.95 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $108.70 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $101.69 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $101.69 | 12 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $99.01 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.36 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $62.44 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $60.68 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $56.48 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $51.47 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.67 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $42.85 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $41.98 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.40 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $33.96 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $31.88 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.64 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.56 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.41 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.51 | 2 | 2025 |
Source payment records
|
|||||
| EVIS EXERA III COLONOVIDEOSCOPE Normalized: evis exera iii colonovideoscope |
Device | Olympus America Inc. | $23.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.33 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $19.44 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Lundbeck LLC | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $8.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 677 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 139 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 141 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 42 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 111 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 171 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 95 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
95 | 22 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
84 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
111 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
118 | 20 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
171 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
677 | 78 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
139 | 15 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1241 | 295 |
| Levothyroxine Sodium | Levothyroxine Sodium | 850 | 185 |
| Eliquis | Apixaban | 677 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 664 | 125 |
| Gabapentin | Gabapentin | 562 | 111 |
| Lisinopril | Lisinopril | 474 | 94 |
| Furosemide | Furosemide | 452 | 104 |
| Omeprazole | Omeprazole | 431 | 125 |
| Potassium Chloride | Potassium Chloride | 415 | 80 |
| Metformin Hcl | Metformin Hcl | 378 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 364 | 85 |
| Famotidine | Famotidine | 362 | 100 |
| Carvedilol | Carvedilol | 355 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 314 | 83 |
| Metoprolol Tartrate | Metoprolol Tartrate | 293 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 248 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 222 | 61 |
| Sertraline Hcl | Sertraline Hcl | 222 | 39 |
| Losartan Potassium | Losartan Potassium | 221 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 219 | 69 |
| Duloxetine Hcl | Duloxetine Hcl | 212 | 40 |
| Trazodone Hcl | Trazodone Hcl | 200 | 46 |
| Donepezil Hcl | Donepezil Hcl | 198 | 40 |
| Levetiracetam | Levetiracetam | 179 | 25 |
| Finasteride | Finasteride | 178 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 175 | 30 |
| Buspirone Hcl | Buspirone Hcl | 174 | 40 |
| Allopurinol | Allopurinol | 171 | 37 |
| Ozempic | Semaglutide | 171 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 161 | 32 |
| Alendronate Sodium | Alendronate Sodium | 146 | 37 |
| Latanoprost | Latanoprost | 146 | 18 |
| Baclofen | Baclofen | 143 | 22 |
| Jardiance | Empagliflozin | 141 | 36 |
| Montelukast Sodium | Montelukast Sodium | 140 | 30 |
| Gemtesa | Vibegron | 139 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 137 | 39 |
| Bupropion Hcl Sr | Bupropion Hcl | 136 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 47 |
| Mirtazapine | Mirtazapine | 136 | 27 |
| Nystatin | Nystatin | 136 | 58 |
| Simvastatin | Simvastatin | 134 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 124 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 16 |
| Trulicity | Dulaglutide | 118 | 20 |
| Spironolactone | Spironolactone | 117 | 30 |
| Meloxicam | Meloxicam | 116 | 37 |
| Ezetimibe | Ezetimibe | 115 | 26 |
| Prednisone | Prednisone | 114 | 44 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 111 | 18 |
| Mounjaro | Tirzepatide | 111 | 22 |
| Divalproex Sodium | Divalproex Sodium | 106 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 28 |
| Bupropion Xl | Bupropion Hcl | 99 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 25 |
| Alprazolam | Alprazolam | 98 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 95 | 22 |
| Torsemide | Torsemide | 94 | 21 |
| Januvia | Sitagliptin Phosphate | 93 | 17 |
| Memantine Hcl | Memantine Hcl | 93 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 26 |
| Xarelto | Rivaroxaban | 84 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 83 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 25 |
| Warfarin Sodium | Warfarin Sodium | 78 | 16 |
| Topiramate | Topiramate | 77 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 76 | 12 |
| Cephalexin | Cephalexin | 74 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 20 |
| Celecoxib | Celecoxib | 73 | 18 |
| Midodrine Hcl | Midodrine Hcl | 73 | 25 |
| Sucralfate | Sucralfate | 73 | 30 |
| Ipratropium Bromide | Ipratropium Bromide | 72 | 16 |
| Levofloxacin | Levofloxacin | 72 | 38 |
| Bumetanide | Bumetanide | 71 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 71 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 70 | suppressed |
| Methylprednisolone | Methylprednisolone | 70 | 53 |
| Clonidine Hcl | Clonidine Hcl | 69 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 13 |
| Azithromycin | Azithromycin | 65 | 48 |
| Tramadol Hcl | Tramadol Hcl | 64 | 16 |
| Insulin Lispro | Insulin Lispro | 61 | 27 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 60 | 19 |
| Ondansetron Odt | Ondansetron | 60 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 14 |
| Clonazepam | Clonazepam | 54 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 17 |
| Farxiga | Dapagliflozin Propanediol | 53 | 24 |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 52 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 25 |
| Lorazepam | Lorazepam | 51 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 15 |
| Atenolol | Atenolol | 50 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 39 |
| Rezvoglar Kwikpen | Insulin Glargine-Aglr | 48 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 17 |
| Acetic Acid | Acetic Acid | 47 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 47 | 11 |
| Fluconazole | Fluconazole | 46 | 26 |
| Naltrexone Hcl | Naltrexone Hcl | 46 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 13 |
| Hydrocortisone | Hydrocortisone | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 23 |
| Spiriva Handihaler | Tiotropium Bromide | 44 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | suppressed |
| Tradjenta | Linagliptin | 43 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 43 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 42 | suppressed |
| Kerendia | Finerenone | 42 | 11 |
| Linzess | Linaclotide | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | 14 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Risperidone | Risperidone | 41 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Olanzapine | Olanzapine | 40 | 13 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Timolol Maleate | Timolol Maleate | 39 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 39 | suppressed |
| Aripiprazole | Aripiprazole | 38 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 11 |
| Temazepam | Temazepam | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 20 |
| Telmisartan | Telmisartan | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 11 |
| Loperamide | Loperamide Hcl | 34 | 16 |
| Xifaxan | Rifaximin | 34 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 33 | suppressed |
| Estradiol | Estradiol | 33 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Lubiprostone | Lubiprostone | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Irbesartan | Irbesartan | 30 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 30 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 22 |
| Premarin | Estrogens, Conjugated | 30 | suppressed |
| Calcium Acetate | Calcium Acetate | 29 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Levemir Flexpen | Insulin Detemir | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Acetazolamide | Acetazolamide | 28 | suppressed |
| Enulose | Lactulose | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 27 | 13 |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | 12 |
| Anastrozole | Anastrozole | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 13 |
| Perphenazine | Perphenazine | 26 | suppressed |
| Amantadine | Amantadine Hcl | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 13 |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | 12 |
| Desmopressin Acetate | Desmopressin Acetate | 24 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | 12 |
| Ammonium Lactate | Ammonium Lactate | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 22 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 22 | suppressed |
| Metolazone | Metolazone | 22 | 11 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Glatopa | Glatiramer Acetate | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Linezolid | Linezolid | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Digoxin | Digoxin | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 16 | 13 |
| Desloratadine | Desloratadine | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 15 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 15 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Zafirlukast | Zafirlukast | 15 | suppressed |
| Zonisamide | Zonisamide | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Alphagan P | Brimonidine Tartrate | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Daptomycin | Daptomycin | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oxaprozin | Oxaprozin | 11 | suppressed |
| Quviviq | Daridorexant Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $47,219.36 · 179 records | SANOFI-AVENTIS U.S. LLC | ABILIFY MAINTENA, ABRYSVO, AIRSUPRA, Auvelity, Azstarys, BREZTRI, CAPLYTA, CAPVAXIVE, CREON, ELIQUIS, EVIS EXERA III COLONOVIDEOSCOPE, FANAPT, FARXIGA, GARDASIL 9, GEMTESA, GVOKE HYPOPEN, HETLIOZ, JARDIANCE, Kerendia, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, UBRELVY, VAXNEUVANCE, VIBERZI, VOQUEZNA, VRAYLAR, VYNDAQEL, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 27 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error